Superior dialytic clearance of β2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis

Kidney International

Volumn 70, Issue 4, 2006, Pages 794-799

  Evenepoel, P ^a   Bammens, B ^a   Verbeke, K ^a   Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adequacy; Dialysis; Middle molecule; Protein bound solute

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; DIALYSIS FLUID; NITROGEN; PARA CRESOL; PERITONEAL DIALYSIS FLUID; UREA;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIALYSATE; DIALYSATE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; BETA 2-MICROGLOBULIN; BLOOD UREA NITROGEN; CREATININE; CRESOLS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATES; RENAL DIALYSIS;

EID: 33747075127     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001640     Document Type: Article

References (35)

1. US Renal Data System: USRDS 2002 Annual Data Report. Atlas of End Stage Renal Disease in The United States. National Insititue of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2002.
2. Eknoyan G, Beck GJ, Cheung AK et al., Hemodialysis (HEMO) Study Group.. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
3. Paniagua R, Amato D, Vonesh E et al., Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
4. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2518-2562.
5. Termorshuizen F, Dekker FW, Van Manen JG et al., NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061-1070.
6. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776.
7. Burkart JM. ADEMEX study and PD adequacy. Blood Purif 2003; 21: 37-41.
8. Pecoits-Filho R, Goncalves S, Barberato SH et al. Impact of residual renal function on volume status in chronic renal failure. Blood Purif 2004; 22: 285-292.
9. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243.
10. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 512-519.
11. Cohen G, Haag-Weber M, Hörl WH. Immune dysfunction in uremia. Kidney Int Suppl 1997; 62: S79-S82.
12. Leypoldt JK, Cheung AK, Caitlin EC et al. Effects of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349-355.
13. Floege J, Ketteler M. Beta2-microglobulin-derived amyloidosis: an update. Kidney Int Suppl 2001; 78: S164-S171.
14. Vanholder R, De Smet R, Lesaffer G. p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 1999; 14: 2813-2815.
15. De Smet R, Van Kaer J, Van Vlem B et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478.
16. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087.
17. Chen TW, Huang TP, Liu MC, Wang ML. The removal index for evaluation of dialysis. Perit Dial Int 1996; 16: 128-134.
18. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 2005; 94: S120-S127.
19. Keshaviah P. Urea kinetic and middle molecule approaches to assessing the adequacy of hemodialysis and CAPD. Kidney Int 1993; 43(Suppl 40): S28-S38.
20. Lameire N, Vanholder R, De Smet R. Uremic toxins and peritoneal dialysis. Kidney Int 2001; 59(Suppl 78): S292-S297.
21. Babb AL, Johansen PJ, Strand MJ et al. Bi-directional permeability of the human peritoneum to middle molecule. Proc Eur Dial Transplant Assoc 1973; 10: 247-257.
22. Chen HC, Guh JY, Lai YH, Tsai JH. Serial changes of serum beta-2-microglobulin in CAPD. Perit Dial Int 1993; 13: 238-239.
23. Blumberg A, Burgi W. Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987; 27: 245-249.
24. Lysaght MJ, Pollock CA, Moran JE et al. Beta-2 microglobulin removal during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9: 29-35.
25. Pickett TM, Cruickshank A, Greenwood RN et al. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif 2002; 20: 161-166.
26. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 2004; 80: 1536-1543.
27. Cummings JH, Hill MJ, Bone ES et al. The effect of meat protein and dietary fiber on colonic function and metabolism. Am J Clin Nutr 1979; 32: 2094-2101.
28. Wu MJ, Chang CS, Cheng CH et al. Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004; 44: 322-327.
29. Kim DJ, Do JH, Huh W et al. Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int 2001; 21: 462-466.
30. Mistry CD, O'Donoghue DJ, Nelson S et al. Kinetic and clinical studies of beta-2-microglobulin in continuous ambulatory peritoneal dialysis: influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 1990; 5: 513-519.
31. Termorshuizen F, Korevaar JC, Dekker FW et al., The Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis. J Am Soc Nephrol 2003; 14: 2851-2860.
32. Jaar BG, Coresh J, Plantinga LC et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143: 174-183.
33. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092.
34. de Loor H, Bammens B, Evenepoel P et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538.
35. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436.